In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

ST-segment elevation in ECG combined with elevated high sensitive troponin-I is associated with worse long-term prognosis in ICU patients

Session Poster Session 2

Speaker Tuija Sabell

Event : Heart Failure 2018

  • Topic : heart failure
  • Sub-topic : Acute Heart Failure: Biomarkers
  • Session type : Poster Session

Authors : T Javanainen (Paris,FR), R Cinotti (Paris,FR), K Cerlinskaite (Paris,FR), S Ishihara (Paris,FR), E Akiyama (Paris,FR), N Vodovar (Paris,FR), E Gayat (Paris,FR), A Mebazaa (Paris,FR)

Authors:
T Javanainen1 , R Cinotti1 , K Cerlinskaite1 , S Ishihara1 , E Akiyama1 , N Vodovar1 , E Gayat1 , A Mebazaa1 , 1Hospital Lariboisiere, Inserm UMR-S 942 and Anesthesia and Critical Care Department - Paris - France ,

Citation:

Background

In critically ill patients, ST-segment elevation (STE) in ECG has been poorly described and its association with long-term outcome is unknown.

Purpose

The aim was to investigate the incidence of STE and its association with 1-year mortality in Intensive Care Unit (ICU) patients.

Methods

The FROG-ICU (NCT 01367093) is a prospective, observational study in 2087 patients, conducted in 21 ICUs in 14 European hospitals. In this sub-study, patients with at least one ECG available during the first 3 days after ICU admission were included. ECGs were analysed digitally and STE was defined according to the Third Universal Definition (1). High sensitive troponin-I (hs-TnI) was measured at inclusion. Three groups of patients were created: 1) No STE and normal hs-TnI. 2) Either STE or elevated hs-TnI. 3) Both STE and elevated hs-TnI.

Cox multivariate regression analysis for 1-year mortality was conducted and the final adjusted model included Simplified Acute Physiology Score II (SAPS II), Charlson Comorbidity Index, gender, hs-TnI at inclusion and cardiac arrest as cause for ICU admission.

Results

In the 738 included patients, 93 (13%) displayed STE. Patients with STE were older (64 years (±18) vs. 59 years (±17), p=0.009), more often male (n=72 (77%) vs. n=425 (66%), p=0.036) and had more comorbidities. Cardiac arrest or cardiogenic shock as cause for ICU admission was more common in STE and hs-TnI was higher (64 ng/l (14-348) vs. 26 ng/l (8-177) p=0.023) (Table). One-year mortality was higher in patients with STE (n=45 (49%) vs. n=206 (32%), p<0.001, Figure A) and STE was associated with mortality in the adjusted cox model (HR 1.52-IC95% (1.09-2.11), p=0.013). Patients with both STE and elevated hs-TnI had two-fold mortality in comparison with no STE and normal hs-TnI (n=25 (49%) vs. n=98 (27%), p<0.001, Figure B).

Conclusions

STE is associated with increased long-term mortality in ICU patients. Combined STE and elevated hs-TnI define patients with the highest mortality risk.

1. Thygesen K et al Third Universal Definition of Myocardial Infarction. J Am Coll Cardiol. 2012 Oct 16;60(16):1581–98.

No ST-elevation n=645 ST-elevation n=93 p
Age, years (SD) 59 (17) 64 (18) 0.009
Male gender, n (%) 425 (66) 72 (77) 0.036
Charlson Comorbidity Index, pts (SD) 2.9 (2.4) 3.7 (2.5) 0.007
SAPS II, pts (SD) 47 (19) 51 (18) 0.021
Cardiac arrest or cardiogenic shock, n (%) 76 (12) 22 (24) 0.003

hs-TnI, ng/L (IQR)

26 (8-177) 64 (14-348) 0.023
Baseline characteristics

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are